Literature DB >> 11334729

The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series.

P Møller1, A Borg, K Heimdal, J Apold, J Vallon-Christersson, E Hovig, L Maehle.   

Abstract

Inherited breast cancer is a heterogenous group of diseases. We examined this heterogeneity in a prospective series of inherited breast and ovarian cancers, previously demonstrated to include 84% of inherited cancers. Ninety-two tumours (65 breast and 27 ovarian) in 82 patients from 70 kindreds were prospectively diagnosed. Fifteen of the breast cancers were in situ, 50 were infiltrating. 40 (49%) of the 82 women carried a BRCA1 mutation, whereas no mutation in BRCA2 was found. Approximately, two-thirds of the BRCA1 mutation carriers had one of the four most frequent Norwegian founder mutations. Ninety-five per cent of the epithelial ovarian cancers occurred in BRCA1 mutation carrying women versus 38% of infiltrating breast cancers and 7% of carcinoma in situ of the breast. The BRCA1 syndrome was phenotypically distinct with invasive, high grade, oestrogen receptor-negative breast cancers and epithelial ovarian cancers. Non-BRCA1/2 inherited breast cancers included carcinoma in situ and lobular carcinoma and were frequently bilateral. Non-BRCA1/2 inherited breast cancer is not associated with epithelial ovarian cancer and in breast cancers has distinct biological characteristics, indicating that the different subgroups of inherited breast cancer may need different healthcare services.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11334729     DOI: 10.1016/s0959-8049(01)00075-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  15 in total

1.  Uptake of BRCA1 genetic testing in adult sisters and daughters of known mutation carriers in Norway.

Authors:  Trine Levin Bodd; Jon Reichelt; Ketil Heimdal; Pal Moller
Journal:  J Genet Couns       Date:  2003-10       Impact factor: 2.537

Review 2.  Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation.

Authors:  Elisabete Weiderpass; Jerzy E Tyczynski
Journal:  Mol Diagn Ther       Date:  2015-12       Impact factor: 4.074

3.  S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Authors:  U Wagner; P Harter; F Hilpert; S Mahner; A Reuß; A du Bois; E Petru; W Meier; P Ortner; K König; K Lindel; D Grab; P Piso; O Ortmann; I Runnebaum; J Pfisterer; D Lüftner; N Frickhofen; F Grünwald; B O Maier; J Diebold; S Hauptmann; F Kommoss; G Emons; B Radeleff; M Gebhardt; N Arnold; G Calaminus; I Weisse; J Weis; J Sehouli; D Fink; A Burges; A Hasenburg; C Eggert
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

4.  Psychological distress in women at risk of hereditary breast/ovarian or HNPCC cancers in the absence of demonstrated mutations.

Authors:  Amy Østertun Geirdal; Jon G Reichelt; Alv A Dahl; Ketil Heimdal; Lovise Maehle; Astrid Stormorken; Pål Møller
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

5.  BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families.

Authors:  Ana Peixoto; Natália Salgueiro; Catarina Santos; Graça Varzim; Patrícia Rocha; Maria José Soares; Deolinda Pereira; Helena Rodrigues; Maria José Bento; António Fráguas; Graça Moura; Fernando Regateiro; Sérgio Castedo; Manuel R Teixeira
Journal:  Fam Cancer       Date:  2006-07-07       Impact factor: 2.375

6.  BRCA1 and BRCA2 mutations in Scotland and Northern Ireland.

Authors: 
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

7.  Towards evidence-based management of inherited breast and breast-ovarian cancer.

Authors:  Pål Møller
Journal:  Hered Cancer Clin Pract       Date:  2004-12-15       Impact factor: 2.857

8.  The relationship between psychological distress and personality in women from families with familial breast/ovarian or hereditary non-polyposis colorectal cancer in the absence of demonstrated mutations.

Authors:  Amy Østertun Geirdal; Alv A Dahl
Journal:  J Genet Couns       Date:  2008-07-08       Impact factor: 2.537

9.  Psychological and cancer-specific distress at 18 months post-testing in women with demonstrated BRCA1 mutations for hereditary breast/ovarian cancer.

Authors:  Jon G Reichelt; Pål Møller; Ketil Heimdal; Alv A Dahl
Journal:  Fam Cancer       Date:  2008-01-25       Impact factor: 2.375

10.  Quality of life and its relation to cancer-related stress in women of families with hereditary cancer without demonstrated mutation.

Authors:  Amy Østertun Geirdal; Lovise Maehle; Ketil Heimdal; Astrid Stormorken; Pål Møller; Alv A Dahl
Journal:  Qual Life Res       Date:  2006-04       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.